Skip to main content

$14m invested to create vaccine for debilitating periodontal gum disease

Denteric launch
Melbourne Dental School Head of School Mike Morgan, CSL Senior Vice President of Research Andrew Nash, University of Melbourne Vice-President (Enterprise) Doron Ben-Meir, COHR CEO & Director of Research Eric Reynolds, Member for Higgins Katie Allen and Brandon Capital Investment Manager Ingmar Wahlqvist at the launch of Denteric.
A vaccine for periodontal gum disease, which affects a third of all adults globally, is in development following a $14 million investment into newly-formed biotech company Denteric Pty Ltd.
The company was set-up to develop and commercialise the research outputs of a long-running programme originating from the University of Melbourne working in collaboration with CSL.
The announcement was made at the official launch of the University’s Centre for Oral Health Research (COHR).
The Series A investment comes from the Medical Research Commercialisation Fund’s (MRCF) Biomedical Translation Fund, a Commonwealth-backed fund managed by Brandon Capital Partners, CSL Ltd., Australia’s largest biotechnology company, and the University of Melbourne.
Denteric will focus on developing a therapeutic vaccine for treating periodontal disease, a debilitating and painful form of gum disease which affects one in three people globally. The disease damages periodontal soft tissue and alveolar bones, which support teeth, due to an accumulation of bacteria.
Moderate to severe periodontitis affects more than 50 per cent of Australians over the age of 65 and is associated with diabetes, heart disease, rheumatoid arthritis, dementia and certain cancers. Poor oral hygiene is the leading cause of periodontitis but there are currently no cures available.
University of Melbourne Professor Eric Reynolds, founder and CEO of the Oral Health CRC, now COHR, said the creation of Denteric is the perfect example of public-private collaboration within the thriving Melbourne Biomedical Precinct.
“My team has been developing this critical treatment for periodontal disease over many years at the University of Melbourne,” Professor Reynolds said. “Today, in a true partnership with the Australian Government and private capital, we have launched a company which will bring a Melbourne-developed gum disease therapy to market.”
MRCF CEO Dr Chris Nave said a treatment for periodontal disease is much-needed as the condition is highly prevalent and affects millions of people globally.
“Current methods for treating periodontal disease are archaic and painful. Looking at the science and market opportunity for Denteric, the Porphyromonas gingivalis (Pg) vaccine research program has great promise and the vaccine would be a blockbuster if it comes to market,” Dr Nave said.
CSL Limited Senior Vice President of Research Dr Andrew Nash said it’s exciting to see the treatment progress to the next stage of development.
“We’ve seen significant potential in this treatment from the early days and we are pleased to continue our support for the program through Series A investment into Denteric. The potential to address unmet medical needs with a new vaccine is very important.”
University of Melbourne Deputy Vice-Chancellor (Research) Professor Jim McCluskey said: “We welcome the significant investment in this critical research, which has the potential to change the lives of people around the world.”
The Series A investment will go towards progressing the Pg vaccine research program. It was a lead program at the Oral Health CRC, which was funded under the Australian Government’s Cooperative Research Centres (CRC) Program from 2003 to 2018.
The Oral Health CRC, which has long been supported by funding from the Victorian Government, Australian Government, CSL and the University of Melbourne, is no longer part of the CRC Program. As part of a new agreement, the CRC has been transformed into the University of Melbourne’s Centre for Oral Health Research, which will come under the Melbourne Dental School.
Those who worked on the Pg vaccine research program as part of the Oral Health CRC will continue to support the established collaborative research and commercialisation relationship with Denteric.
The company is looking to commence its first clinical trial in humans in the next two to three years.


SOURCE 

Comments

Post a Comment

Popular posts from this blog

Apple Invents a new Health feature for AirPods that will provide diagnosis & monitoring of Bruxism

Today the US Patent & Trademark Office published a patent application from Apple that relates to a possible future health related feature regarding the diagnosis and monitoring of bruxism using motion sensors in AirPods. Teeth grinding and jaw clenching (bruxism) are the most common parafunctional behavior manifested during sleep and awakeness. Awake bruxism has been mostly associated with emotions like anxiety, stress, frustration or tension. During sleep it causes sleep disorders and arousals. Individuals are mostly unaware of the occurrent and severity of their bruxing habits. The unawareness results in a myriad of orofacial muscle pain and dental consequences like teeth damage, wear and fractures. Commercial devices in dental practice to monitor and treat bruxism are expensive, inconvenient for frequent daily use. For instance, Polysomnography (PSG) studies that target the monitoring of sleep bruxism, require patients to sleep in a clinical setting overnight. Further,
Post a Comment
Read more

Esthetic Oral Rehabilitation with Veneers

Porcelain veneers had long been considered to be only an esthetic solution. However, their range of indications has been steadily increasing, making ceramic veneers a highly viable alternative to classic, far more invasive forms of restorative treatment. Today, veneers can be used to handle esthetics (discolored teeth, fractured and worn teeth, diastemas, dental defects, etc.) and to restore the biomechanics of the dentition, as well as many other indications. Classifications of Veneer Preparations Referred to as no, minimal, or conventional preparation, veneer classifications—or lack there of—create a large gray zone of misunderstanding and miscommunication with patients and within the dental profession. Left unanswered, questions regarding tooth structure removal, finish lines and margins, and other aspects can cause confusion in practice. Flaws and inaccuracies in previously proposed preparation guidelines make those guidelines irrelevant . To dissolve uncertainty, this v
Post a Comment
Read more

Orthodontics for Esthetic Dental Treatment: Symbiotic Efforts for Optimal Results

Human fascination with beauty and esthetic trends is continuously evolving; moreover, public awareness and desire to improve facial appearances are at the highest level. This trend of heightened public awareness and expectation is paving a new way of dentistry toward a more comprehensive approach with esthetic principles at its core. The oral health of the patient and his or her dentition are fundamental in dental treatment. However, the final esthetic outcome should be among the first steps in treatment planning. The ideal esthetic approach in dental treatment planning often requires a multidisciplinary approach engaging various dental professionals. This process requires thorough communication among dental practitioners and a basic understanding of what each discipline can provide. FACIAL ANALYSIS Facial evaluation is an integral part of patient examination. It starts with evaluating facial symmetry, as symmetric faces are considered more beautiful than those that are n
Post a Comment
Read more